Advertisement
Screener

NURIX THERAPEUTICS, INC. (NRIX) Increase Decrease In Operating Lease Liability

2.8 / 5 stars · 68/120 Roast Me

NURIX THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability

NURIX THERAPEUTICS, INC. (NRIX) reported Increase Decrease In Operating Lease Liability of -$352.00 thousand for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-07-09

  • NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-05-31 was -$557.00K.
  • NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-02-28 was $205.00K.
  • NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-11-30 was -$756.00K.
  • NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-08-31 was -$1.23M.
  • NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2025 was -$5.07M.
  • NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2024 was -$6.42M.
  • NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was -$6.27M.
  • NURIX THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2022 was -$4.87M.
Period endIncrease Decrease In Operating Lease Liability 3 monthIncrease Decrease In Operating Lease Liability 6 monthIncrease Decrease In Operating Lease Liability 9 monthIncrease Decrease In Operating Lease Liability 12 month
2026-05-31-$557.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09
-$352.00K
10-Q · filed 2026-07-09
-$1.11M
derived: sum of 3 quarters · filed 2026-07-09
-$2.34M
derived: sum of 4 quarters · filed 2026-07-09
2026-02-28$205.00K
10-Q · filed 2026-04-08
-$551.00K
derived: sum of 2 quarters · filed 2026-04-08
-$1.78M
derived: sum of 3 quarters · filed 2026-04-08
-$3.18M
derived: sum of 4 quarters · filed 2026-07-09
2025-11-30-$756.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28
-$1.99M
derived: sum of 2 quarters · filed 2026-01-28
-$3.39M
derived: sum of 3 quarters · filed 2026-07-09
-$5.07M
10-K · filed 2026-01-28
2025-08-31-$1.23M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09
-$2.63M
derived: sum of 2 quarters · filed 2026-07-09
-$4.31M
10-Q · filed 2025-10-09
-$5.96M
derived: sum of 4 quarters · filed 2026-07-09
2025-05-31-$1.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09
-$3.08M
10-Q · filed 2026-07-09
-$4.73M
derived: sum of 3 quarters · filed 2026-07-09
-$6.41M
derived: sum of 4 quarters · filed 2026-07-09
2025-02-28-$1.68M
10-Q · filed 2026-04-08
-$3.33M
derived: sum of 2 quarters · filed 2026-04-08
-$5.01M
derived: sum of 3 quarters · filed 2026-04-08
-$6.64M
derived: sum of 4 quarters · filed 2026-04-08
2024-11-30-$1.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28
-$3.33M
derived: sum of 2 quarters · filed 2026-01-28
-$4.96M
derived: sum of 3 quarters · filed 2026-01-28
-$6.42M
10-K · filed 2026-01-28
2024-08-31-$1.68M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09
-$3.31M
derived: sum of 2 quarters · filed 2025-10-09
-$4.77M
10-Q · filed 2025-10-09
-$6.10M
derived: sum of 4 quarters · filed 2026-01-28
2024-05-31-$1.63M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09
-$3.09M
10-Q · filed 2025-07-09
-$4.42M
derived: sum of 3 quarters · filed 2026-01-28
-$6.28M
derived: sum of 4 quarters · filed 2026-01-28
2024-02-29-$1.46M
10-Q · filed 2025-04-08
-$2.79M
derived: sum of 2 quarters · filed 2026-01-28
-$4.64M
derived: sum of 3 quarters · filed 2026-01-28
-$6.42M
derived: sum of 4 quarters · filed 2026-01-28
2023-11-30-$1.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28
-$3.18M
derived: sum of 2 quarters · filed 2026-01-28
-$4.97M
derived: sum of 3 quarters · filed 2026-01-28
-$6.27M
10-K · filed 2026-01-28
2023-08-31-$1.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11
-$3.64M
derived: sum of 2 quarters · filed 2024-10-11
-$4.94M
10-Q · filed 2024-10-11
-$6.13M
derived: sum of 4 quarters · filed 2025-01-28
2023-05-31-$1.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11
-$3.08M
10-Q · filed 2024-07-11
-$4.28M
derived: sum of 3 quarters · filed 2025-01-28
-$5.41M
derived: sum of 4 quarters · filed 2025-01-28
2023-02-28-$1.30M
10-Q · filed 2024-04-10
-$2.49M
derived: sum of 2 quarters · filed 2025-01-28
-$3.63M
derived: sum of 3 quarters · filed 2025-01-28
-$5.76M
derived: sum of 4 quarters · filed 2025-01-28
2022-11-30-$1.19M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28
-$2.32M
derived: sum of 2 quarters · filed 2025-01-28
-$4.46M
derived: sum of 3 quarters · filed 2025-01-28
-$4.87M
10-K · filed 2025-01-28
2022-08-31-$1.13M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12
-$3.27M
derived: sum of 2 quarters · filed 2023-10-12
-$3.68M
10-Q · filed 2023-10-12
-$6.39M
derived: sum of 4 quarters · filed 2023-10-12
2022-05-31-$2.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13
-$2.55M
10-Q · filed 2023-07-13
-$5.26M
derived: sum of 3 quarters · filed 2023-07-13
-$6.14M
derived: sum of 4 quarters · filed 2023-07-13
2022-02-28-$408.00K
10-Q · filed 2023-04-13
-$3.12M
derived: sum of 2 quarters · filed 2023-04-13
-$4.00M
derived: sum of 3 quarters · filed 2023-04-13
-$4.82M
derived: sum of 4 quarters · filed 2023-04-13
2021-11-30-$2.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09
-$3.59M
derived: sum of 2 quarters · filed 2023-02-09
-$4.41M
derived: sum of 3 quarters · filed 2023-02-09
-$5.14M
10-K · filed 2023-02-09
2021-08-31-$877.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06
-$1.70M
derived: sum of 2 quarters · filed 2022-10-06
-$2.43M
10-Q · filed 2022-10-06
2021-05-31-$818.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07
-$1.55M
10-Q · filed 2022-07-07
2021-02-28-$737.00K
10-Q · filed 2022-04-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Immunome Inc. (IMNM)United States$2.538B-9.45
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36